PROCEPT BioRobotics (PRCT) Aandelenoverzicht
PROCEPT BioRobotics Corporation, een chirurgisch robotica bedrijf, ontwikkelt transformatieve oplossingen in de urologie in de Verenigde Staten en internationaal. Meer informatie
| Sneeuwvlok Score | |
|---|---|
| Waardering | 1/6 |
| Toekomstige groei | 1/6 |
| Prestaties in het verleden | 0/6 |
| Financiële gezondheid | 6/6 |
| Dividenden | 0/6 |
PRCT Community Fair Values
Create NarrativeSee what 39 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Top Community Narratives
US$25.26
FV
17.3% ondergewaardeerd intrinsieke korting66
users have viewed this narrative0users have liked this narrative
1users have commented on this narrative
3users have followed this narrative
PROCEPT BioRobotics Corporation Concurrenten
Prijsgeschiedenis en prestaties
| Historische aandelenkoersen | |
|---|---|
| Huidige aandelenkoers | US$20.89 |
| 52 Week Hoogtepunt | US$62.17 |
| 52 Week Laag | US$19.35 |
| Bèta | 0.87 |
| 1 maand verandering | -28.19% |
| 3 maanden verandering | -9.96% |
| 1 Jaar Verandering | -63.12% |
| 3 jaar verandering | -42.77% |
| 5 jaar verandering | n/a |
| Verandering sinds IPO | -50.19% |
Recent nieuws en updates
Analyseartikel • Jun 20
PROCEPT BioRobotics (PRCT) Stock Could Be 14% Undervalued After Growth Outlook Holds
A fresh batch of commentary on PROCEPT BioRobotics (PRCT) is drawing attention to the stock after a recent summary highlighted rapid revenue scaling, expanding gross margins, and slightly lower management guidance. See our latest analysis for PROCEPT BioRobotics. Despite the fresh commentary around high revenue growth and expanding margins, PROCEPT BioRobotics’ share price return tells a different story. The stock is down 24.9% over 30 days and the 1 year total shareholder return has declined...
Nieuw narratief • Jun 18
PROCEPT BioRobotics sees 17.69% revenue growth and aims for 12.94% profit margin
I have been an investor in PRCT since before IPO. The wild fluctuations in share price recently make no sense.
Narratiefupdate • Jun 16
PRCT: Aquablation Adoption And Guideline Support Will Drive Long Term Upside
Analysts have trimmed their fair value estimate for PROCEPT BioRobotics from $46.67 to $37.00. This reflects reduced price targets and more cautious procedure forecasts as competition and inventory uncertainty weigh on near term expectations.
Narratiefupdate • Jun 02
PRCT: Rising Competition Will Likely Cap Future Penetration And Repricing
Analysts lifted their price target on PROCEPT BioRobotics to $30, framing the change alongside slightly moderated assumptions for revenue growth and margins as they reassess how recent market headwinds and a more competitive benign prostatic hyperplasia field could influence the company's long term penetration of Aquablation systems. Analyst Commentary Recent Street research highlights a more cautious tone around PROCEPT BioRobotics, even with a US$30 price target in focus.Recent updates
Analyseartikel • Jun 20
PROCEPT BioRobotics (PRCT) Stock Could Be 14% Undervalued After Growth Outlook Holds
A fresh batch of commentary on PROCEPT BioRobotics (PRCT) is drawing attention to the stock after a recent summary highlighted rapid revenue scaling, expanding gross margins, and slightly lower management guidance. See our latest analysis for PROCEPT BioRobotics. Despite the fresh commentary around high revenue growth and expanding margins, PROCEPT BioRobotics’ share price return tells a different story. The stock is down 24.9% over 30 days and the 1 year total shareholder return has declined...Nieuw narratief • Jun 18
PROCEPT BioRobotics sees 17.69% revenue growth and aims for 12.94% profit margin
I have been an investor in PRCT since before IPO. The wild fluctuations in share price recently make no sense.Narratiefupdate • Jun 16
PRCT: Aquablation Adoption And Guideline Support Will Drive Long Term Upside
Analysts have trimmed their fair value estimate for PROCEPT BioRobotics from $46.67 to $37.00. This reflects reduced price targets and more cautious procedure forecasts as competition and inventory uncertainty weigh on near term expectations.Narratiefupdate • Jun 02
PRCT: Rising Competition Will Likely Cap Future Penetration And Repricing
Analysts lifted their price target on PROCEPT BioRobotics to $30, framing the change alongside slightly moderated assumptions for revenue growth and margins as they reassess how recent market headwinds and a more competitive benign prostatic hyperplasia field could influence the company's long term penetration of Aquablation systems. Analyst Commentary Recent Street research highlights a more cautious tone around PROCEPT BioRobotics, even with a US$30 price target in focus.
Narratiefupdate • May 03
PRCT: New BPH Guideline Endorsements Will Support Long Term Procedure Adoption
Analysts have modestly trimmed their average price target for PROCEPT BioRobotics to about $30. Recent cuts from several firms, reflecting concerns over Q4 results, guidance resets and execution risks in expanding Aquablation adoption, were partially offset by at least one subsequent upward revision.Narratiefupdate • Apr 19
PRCT: Execution Reset After Q4 Miss Will Likely Drive Bearish Repricing
Analyst price targets for PROCEPT BioRobotics have reset meaningfully lower, with the fair value estimate moving from about $38.00 to roughly $20.80. Analysts are factoring in recent Q4 misses, reduced 2026 guidance, concerns around Aquablation adoption in a highly competitive benign prostatic hyperplasia market, and questions about the timing and impact of the company's reorganization and pricing changes.Narratiefupdate • Apr 05
PRCT: Reset Guidance And New BPH Endorsements Will Support Long Term Rebound
The analyst price target for PROCEPT BioRobotics has been revised slightly lower, from about $32.50 to roughly $30.44, as analysts factor in recent Q4 results, reduced 2026 guidance, and concerns about slower Aquablation adoption in a highly competitive benign prostatic hyperplasia market. Analyst Commentary Street research around PROCEPT BioRobotics has shifted toward more cautious positioning, with a cluster of lower price targets and a mix of neutral and negative ratings following Q4 results and updated 2026 guidance.Narratiefupdate • Mar 21
PRCT: Commercial Reorganization And HYDROS Rollout Will Support Long Term Rebound Potential
Analysts have cut their average price targets on PROCEPT BioRobotics toward the $30 range, with the fair value estimate moving from about $62 to roughly $46.67 as they factor in recent Q4 shortfalls, reduced 2026 guidance, and concerns about slower Aquablation adoption in a competitive benign prostatic hyperplasia market. Analyst Commentary Recent research updates paint a mixed picture, with most firms trimming price targets after Q4 results and reduced 2026 guidance.Narratiefupdate • Mar 07
PRCT: Long Term Margin Targets And Guidance Reset Will Support Rebound
The analyst price target for PROCEPT BioRobotics has been revised from about $50.73 to $32.50 as analysts factor in recent Q4 misses, reduced 2026 guidance, questions around market penetration for Aquablation, and concerns about execution on sales and discounting changes in a competitive BPH market. Analyst Commentary Street research around PROCEPT BioRobotics has shifted toward a more cautious stance, with several firms cutting price targets and reassessing expectations after Q4 results and lower 2026 guidance.Narratiefupdate • Feb 21
PRCT: Higher Modeled Margins And Investor Day Focus Will Support Rebound Potential
Analysts kept their average price target for PROCEPT BioRobotics steady at $62.00, citing updated assumptions that reflect slightly higher modeled revenue growth and profit margin, as well as a lower future P/E multiple. What's in the News PROCEPT BioRobotics scheduled an Analyst/Investor Day titled "PROCEPT BioRobotics Corporation: Analyst/Investor Day," providing the market with a dedicated forum to hear management's latest updates and focus areas (Key Developments).Narratiefupdate • Feb 07
PRCT: Analyst Day And Margin Outlook Will Support Future Stock Rebound
Analysts have modestly adjusted their fair value outlook for PROCEPT BioRobotics, with the updated price target now framed around $50.73 as they refine assumptions on the discount rate, a profit margin of about 13.57%, and a forward P/E of roughly 46.37x. What's in the News PROCEPT BioRobotics scheduled an Analyst/Investor Day event, described as "PROCEPT BioRobotics Corporation Analyst/Investor Day," signaling a focused update for the professional investment community on the business and outlook (Key Developments).Narratiefupdate • Jan 24
PRCT: Inline Revenue Guidance And Conservative Outlook Will Support Rebound Potential
Narrative Update Analysts have cut their fair value estimate for PROCEPT BioRobotics from US$85.00 to US$62.00, citing more conservative views on revenue growth, profit margins, and a much higher assumed future P/E. However, some still see recent stock moves as a stronger reaction than these adjustments alone would suggest.Narratiefupdate • Jan 10
PRCT: Earnings Volatility Setup Will Likely Drive Future Share Repricing
Analysts have reset their price target framework for PROCEPT BioRobotics, with the fair value estimate moving from about $51 to $38 as they factor in lower published targets around $50, modest tweaks to growth and margin assumptions, and a lower future P/E multiple. They still cite what they see as conservative company guidance and potential for outsized stock reactions around quarterly results.Narratiefupdate • Dec 25
PRCT: Stock Reaction Will Recover As Conservative Guidance Sets Up Future Rebound
Analysts have nudged their average price target on PROCEPT BioRobotics slightly higher to about $50.73 from roughly $49.90, citing still healthy growth expectations, a modestly richer future earnings multiple, and the view that recent stock volatility and cautious guidance have led to an overly conservative market reaction. Analyst Commentary Recent Street research reflects a recalibration of expectations rather than a fundamental shift in conviction, with ownership sentiment remaining generally constructive even as price targets move lower.Narratiefupdate • Dec 11
PRCT: Stock Reaction Will Recover As Conservative Guidance And Pullback Normalize
Analysts have modestly reduced their price target on PROCEPT BioRobotics from about $52 to roughly $50 per share, reflecting slightly lower profit margin expectations even as they argue the recent share price reaction to conservative guidance and sector-wide volatility appears overdone. Analyst Commentary Bullish analysts emphasize that the recalibrated $50 price target still implies meaningful upside from current levels, as they view the recent pullback as disconnected from the company’s underlying growth trajectory and operational execution.Narratiefupdate • Nov 27
PRCT: Stock Reaction Will Recover As Guidance Proves Conservative
Analysts have lowered their price target for PROCEPT BioRobotics from $55.60 to $52.10 per share, citing a mix of cautious company guidance and continued anticipation of healthy revenue growth, even with recent market volatility. Analyst Commentary Recent analyst reports reflect a mix of optimistic outlooks and measured caution for PROCEPT BioRobotics, as price targets have been adjusted downward in the context of ongoing market volatility and evolving company guidance.Narratiefupdate • Nov 13
PRCT: Stock Reaction Will Normalize As Sector Volatility Subsides
The analyst consensus fair value target for PROCEPT BioRobotics has been reduced by approximately $5 to $55.60. Analysts attribute the adjustment to updated sales guidance and expectations of continued volatility in the medtech sector.Narratiefupdate • Oct 30
PRCT: Share Price Will Likely React Sharply To Upcoming Earnings Data
Analysts have lowered their price target for PROCEPT BioRobotics from $62.70 to $60.90, citing broad MedTech market volatility and anticipated stock fluctuations. This comes despite expectations of healthy Q3 financial performance.Narratiefupdate • Oct 16
Clinical Adoption And Global Expansion Will Redefine Healthcare
Analysts have updated their price target for PROCEPT BioRobotics, lowering it from $64 to $50 per share. They cite expectations for healthy revenue, but also note increased market volatility and cautious investor sentiment in the MedTech sector.Analyseartikel • Sep 26
Is PROCEPT BioRobotics (NASDAQ:PRCT) A Risky Investment?
The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...Seeking Alpha • Aug 14
Procept BioRobotics: Increasing Average Selling Price, Initiate At Buy
Summary Procept BioRobotics Corporation is in the early stages of penetrating a massive $20B BPH surgery market with its innovative, recurring-revenue robotic systems. The company’s strong revenue and install base growth, favorable reimbursement, and increasing ASPs support my buy rating and $44 fair value estimate. Gross margin expansion is expected from pricing power, scale, and cost control, with break-even projected by FY27 and improving operating leverage thereafter. Key risks include competition from established therapies, potential share dilution, and the need for international expansion and sales force investment. Read the full article on Seeking AlphaAnalyseartikel • Aug 09
What You Can Learn From PROCEPT BioRobotics Corporation's (NASDAQ:PRCT) P/S After Its 34% Share Price Crash
NasdaqGM:PRCT 1 Year Share Price vs Fair Value Explore PROCEPT BioRobotics's Fair Values from the Community and select...Narratiefupdate • Aug 08
Clinical Adoption And Global Expansion Will Redefine Healthcare
The modest reduction in PROCEPT BioRobotics’ consensus price target to $65.75 reflects a slight downward revision in the company’s future P/E multiple, while profitability remains stable. What's in the News Raised full-year 2025 revenue guidance to $325.5 million, representing 45% year-over-year growth; projected net loss for 2025 is $83.5 million.Analyseartikel • Aug 08
PROCEPT BioRobotics Corporation (NASDAQ:PRCT) Just Reported, And Analysts Assigned A US$65.75 Price Target
A week ago, PROCEPT BioRobotics Corporation ( NASDAQ:PRCT ) came out with a strong set of quarterly numbers that could...Analyseartikel • Apr 27
US$77.00: That's What Analysts Think PROCEPT BioRobotics Corporation (NASDAQ:PRCT) Is Worth After Its Latest Results
PROCEPT BioRobotics Corporation ( NASDAQ:PRCT ) just released its latest first-quarter results and things are looking...Analyseartikel • Apr 18
Investors Appear Satisfied With PROCEPT BioRobotics Corporation's (NASDAQ:PRCT) Prospects
PROCEPT BioRobotics Corporation's ( NASDAQ:PRCT ) price-to-sales (or "P/S") ratio of 12.9x may look like a poor...
Nieuw narratief • Mar 21
HYDROS Robotic System Launch And Aquablation Trials Will Drive Future Market Expansion
Launch of HYDROS Robotic System and FDA approvals likely to increase procedural adoption and drive revenue growth.Seeking Alpha • Mar 11
Procept BioRobotics: Strong Growth, But Profitability Seems Far Away
Summary PROCEPT BioRobotics shows strong revenue growth and expanding market presence but struggles with profitability and rising operational costs. The company’s HYDROS robotic system and consumables business are driving revenue, with significant expansion in the U.S. and promising international growth. The FDA’s clearance for Aquablation therapy in prostate cancer patients presents a long-term opportunity, though profitability remains a distant goal. Despite a high valuation and solid market position, ongoing losses and cash burn warrant a "Hold" rating for PRCT. Read the full article on Seeking AlphaAnalyseartikel • Feb 28
PROCEPT BioRobotics Corporation (NASDAQ:PRCT) Just Reported, And Analysts Assigned A US$93.86 Price Target
PROCEPT BioRobotics Corporation ( NASDAQ:PRCT ) came out with its full-year results last week, and we wanted to see how...Analyseartikel • Dec 05
What You Can Learn From PROCEPT BioRobotics Corporation's (NASDAQ:PRCT) P/S
You may think that with a price-to-sales (or "P/S") ratio of 26.9x PROCEPT BioRobotics Corporation ( NASDAQ:PRCT ) is a...Seeking Alpha • Nov 26
Procept BioRobotics: Continued Growth Runway Ahead
Summary PRCT's Q3 sales were up 66% YoY, and gross margins reached a record 63%. Management forecasts $223mm in sales this year, with a 64% top-line growth. The business model ensures recurring revenue and operating leverage. Read the full article on Seeking AlphaAnalyseartikel • Oct 31
Earnings Update: Here's Why Analysts Just Lifted Their PROCEPT BioRobotics Corporation (NASDAQ:PRCT) Price Target To US$102
A week ago, PROCEPT BioRobotics Corporation ( NASDAQ:PRCT ) came out with a strong set of third-quarter numbers that...Seeking Alpha • Sep 12
Procept BioRobotics: New Hydros Aquablation System To Fuel Next Leg Of Growth
Summary Procept Biorobotics is a top performer in the medical device industry, offering relief for men with BPH. The company's minimally invasive procedure is experiencing rapid growth in both system sales and procedures. Approval of the new HYDROS system is expected to drive further growth for the company in the future. Read the full article on Seeking AlphaSeeking Alpha • Aug 27
Procept BioRobotics: Risk Capital Unlock With FDA Hydros Approval
Summary The FDA's approval of Procept's Hrydos system is a meaningful catalyst to the investment debate. Investors have added ~$5/share in market value since the announcement. PRCT's Q2 '24 numbers were equally as strong and exhibited an extensive runway of growth ahead in my view. Read the full article on Seeking AlphaAnalyseartikel • Aug 25
Investors Appear Satisfied With PROCEPT BioRobotics Corporation's (NASDAQ:PRCT) Prospects As Shares Rocket 28%
PROCEPT BioRobotics Corporation ( NASDAQ:PRCT ) shareholders would be excited to see that the share price has had a...Analyseartikel • Aug 04
Here's What Analysts Are Forecasting For PROCEPT BioRobotics Corporation (NASDAQ:PRCT) After Its Second-Quarter Results
PROCEPT BioRobotics Corporation ( NASDAQ:PRCT ) defied analyst predictions to release its quarterly results, which were...Analyseartikel • May 21
PROCEPT BioRobotics Corporation's (NASDAQ:PRCT) P/S Is Still On The Mark Following 37% Share Price Bounce
The PROCEPT BioRobotics Corporation ( NASDAQ:PRCT ) share price has done very well over the last month, posting an...Analyseartikel • Apr 05
The Price Is Right For PROCEPT BioRobotics Corporation (NASDAQ:PRCT)
You may think that with a price-to-sales (or "P/S") ratio of 17.1x PROCEPT BioRobotics Corporation ( NASDAQ:PRCT ) is a...Analyseartikel • Mar 01
US$56.67 - That's What Analysts Think PROCEPT BioRobotics Corporation (NASDAQ:PRCT) Is Worth After These Results
The full-year results for PROCEPT BioRobotics Corporation ( NASDAQ:PRCT ) were released last week, making it a good...Analyseartikel • Feb 07
Despite Lacking Profits PROCEPT BioRobotics (NASDAQ:PRCT) Seems To Be On Top Of Its Debt
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...Analyseartikel • Dec 14
Market Participants Recognise PROCEPT BioRobotics Corporation's (NASDAQ:PRCT) Revenues Pushing Shares 26% Higher
PROCEPT BioRobotics Corporation ( NASDAQ:PRCT ) shareholders have had their patience rewarded with a 26% share price...Rendement voor aandeelhouders
| PRCT | US Medical Equipment | US Markt | |
|---|---|---|---|
| 7D | -0.7% | -1.3% | 0.7% |
| 1Y | -63.1% | -18.6% | 20.6% |
Rendement versus industrie: PRCT presteerde slechter dan de US Medical Equipment -sector, die het afgelopen jaar een rendement van -18.6 % opleverde.
Rendement versus markt: PRCT presteerde slechter dan US Market, dat het afgelopen jaar een rendement van 20.6 % opleverde.
Prijsvolatiliteit
| PRCT volatility | |
|---|---|
| PRCT Average Weekly Movement | 9.9% |
| Medical Equipment Industry Average Movement | 8.5% |
| Market Average Movement | 7.3% |
| 10% most volatile stocks in US Market | 16.6% |
| 10% least volatile stocks in US Market | 3.2% |
Stabiele aandelenkoers: PRCT heeft de afgelopen 3 maanden geen significante prijsvolatiliteit gekend vergeleken met de US markt.
Volatiliteit in de loop van de tijd: De wekelijkse volatiliteit ( 10% ) van PRCT is het afgelopen jaar stabiel geweest.
Over het bedrijf
| Opgericht | Werknemers | CEO | Website |
|---|---|---|---|
| 2007 | 888 | Larry Wood | www.procept-biorobotics.com |
PROCEPT BioRobotics Corporation, een chirurgisch robotica bedrijf, ontwikkelt transformatieve oplossingen in de urologie in de Verenigde Staten en internationaal. Het bedrijf ontwikkelt, produceert en verkoopt het AquaBeam Robotic System, een beeldgestuurd chirurgisch robotsysteem voor gebruik in minimaal invasieve urologische chirurgie gericht op de behandeling van goedaardige prostaathyperplasie. Het bedrijf levert ook het HYDROS Robotic System, een beeldgestuurde robottherapie voor aquablatie om mannen te behandelen die lijden aan symptomen van de lagere urinewegen als gevolg van goedaardige prostaathyperplasie.
PROCEPT BioRobotics Corporation Samenvatting
| PRCT fundamentele statistieken | |
|---|---|
| Marktkapitalisatie | US$1.12b |
| Inkomsten(TTM) | -US$102.47m |
| Inkomsten(TTM) | US$322.02m |
3.7x
P/S-verhouding-11.6x
Koers/WinstverhoudingIs PRCT overgewaardeerd?
Zie Reële waarde en waarderingsanalyseInkomsten en omzet
| PRCT resultatenrekening (TTM) | |
|---|---|
| Inkomsten | US$322.02m |
| Kosten van inkomsten | US$116.01m |
| Brutowinst | US$206.01m |
| Overige uitgaven | US$308.49m |
| Inkomsten | -US$102.47m |
Laatst gerapporteerde inkomsten
Mar 31, 2026
Volgende inkomensdatum
n.v.t.
| Winst per aandeel (EPS) | -1.80 |
| Brutomarge | 63.97% |
| Nettowinstmarge | -31.82% |
| Schuld/Eigen Vermogen Verhouding | 14.9% |
Hoe presteerde PRCT op de lange termijn?
Bekijk historische prestaties en vergelijkingBedrijfsanalyse en status van financiële gegevens
| Gegevens | Laatst bijgewerkt (UTC-tijd) |
|---|---|
| Bedrijfsanalyse | 2026/07/10 23:01 |
| Aandelenkoers aan het einde van de dag | 2026/07/10 00:00 |
| Inkomsten | 2026/03/31 |
| Jaarlijkse inkomsten | 2025/12/31 |
Gegevensbronnen
De gegevens die gebruikt zijn in onze bedrijfsanalyse zijn afkomstig van S&P Global Market Intelligence LLC. De volgende gegevens worden gebruikt in ons analysemodel om dit rapport te genereren. De gegevens zijn genormaliseerd, waardoor er een vertraging kan optreden voordat de bron beschikbaar is.
| Pakket | Gegevens | Tijdframe | Voorbeeld Amerikaanse bron * |
|---|---|---|---|
| Financiële gegevens bedrijf | 10 jaar |
| |
| Consensus schattingen analisten | +3 jaar |
|
|
| Marktprijzen | 30 jaar |
| |
| Eigendom | 10 jaar |
| |
| Beheer | 10 jaar |
| |
| Belangrijkste ontwikkelingen | 10 jaar |
|
* Voorbeeld voor effecten uit de VS, voor niet-Amerikaanse effecten worden gelijkwaardige formulieren en bronnen gebruikt.
Tenzij anders vermeld zijn alle financiële gegevens gebaseerd op een jaarperiode, maar worden ze elk kwartaal bijgewerkt. Dit staat bekend als Trailing Twelve Month (TTM) of Last Twelve Month (LTM) gegevens. Meer informatie.
Analysemodel en Snowflake
Details van het analysemodel dat is gebruikt om dit rapport te genereren zijn beschikbaar op onze Github-pagina, we hebben ook handleidingen over hoe u onze rapporten kunt gebruiken en tutorials op YouTube.
Leer meer over het team van wereldklasse dat het Simply Wall St-analysemodel heeft ontworpen en gebouwd.
Industrie en sector
Onze industrie- en sectormetrics worden elke 6 uur berekend door Simply Wall St, details van ons proces zijn beschikbaar op Github.
Bronnen van analisten
PROCEPT BioRobotics Corporation wordt gevolgd door 22 analisten. 13 van deze analisten hebben de schattingen van de omzet of winst ingediend die zijn gebruikt als input voor ons rapport. Inzendingen van analisten worden de hele dag door bijgewerkt.
| Analist | Instelling |
|---|---|
| David Rescott | Baird |
| Stephanie Piazzola | BofA Global Research |
| Stephanie Elghazi | BofA Global Research |